PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe) (PRIMe)
Sponsor: Agendia
A observational or N/A phase clinical study on Breast Cancer, this trial is completed. The trial is conducted by Agendia and has accumulated 9 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Sep 2019 — Jan 2021 [monthly]
Completed
Status: Unknown Status → Completed
▶ Show 4 earlier versions
-
Jun 2018 — Sep 2019 [monthly]
Unknown Status
-
Apr 2018 — Jun 2018 [monthly]
Unknown Status
Phase: NA → None
-
Jul 2017 — Apr 2018 [monthly]
Unknown Status NA
Status: Recruiting → Unknown Status
-
Jan 2017 — Jul 2017 [monthly]
Recruiting NA
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Agendia
- West German Study Group
For direct contact, visit the study record on ClinicalTrials.gov .